International Scholarly Research Notices

Research Article

Retrospective Study of Japanese Patients with Schizophrenia Treated with Aripiprazole

Table 1

Changes of clinical indicators of before and after switch to aripiprazole.
 Responsive group ( 𝑛 = 1 4 )Nonresponsive group ( 𝑛 = 1 3 )
 Before
(Mean ± SD)		After
(Mean ± SD)		 𝑍 value 𝑃 value*Before
(Mean ± SD)		After
(Mean ± SD)		 𝑍 value 𝑃 value*
Mean daily dosage         
 Antipsychotics
 (CP equivalent; mg)		 4 8 9 . 4 ± 3 3 5 . 5 4 4 8 . 6 ± 1 8 4 . 3 −0.28 0.78 5 2 7 . 8 ± 3 5 9 . 9 7 7 1 . 0 ± 5 1 4 . 5 −1.73 0.08
 Antiparkinson drug
 (BP equivalent; mg)		 1 . 0 ± 1 . 5 0 . 2 3 ± 0 . 6 −1.80 0.07 1 . 5 ± 2 . 4 0 . 9 ± 1 . 8 −0.94 0.35
Psychosis        
 BPRS total score 3 2 . 6 ± 8 . 9 2 8 . 1 ± 1 2 . 2 −2.28 0.04 3 3 . 7 ± 1 0 . 2 3 2 . 8 ± 1 0 . 9 −0.57 0.58
Glucose and lipid metabolism        
 TP (g/dL) 6 . 7 ± 0 . 5 6 . 9 ± 0 . 9 −1.20 0.23 6 . 5 ± 0 . 7 6 . 7 ± 0 . 6 −0.79 0.43
 ALB (g/dL) 4 . 0 ± 0 . 4 3 . 9 ± 0 . 7 −1.16 0.25 3 . 9 ± 0 . 6 4 . 0 ± 0 . 4 −0.05 0.96
 A/G ratio 1 . 4 ± 0 . 3 1 . 4 ± 0 . 3 −0.56 0.58 1 . 6 ± 0 . 3 1 . 5 ± 0 . 3 −1.30 0.20
 T-cho (mg/dL) 1 7 2 . 9 ± 3 6 . 8 1 7 8 . 5 ± 4 1 . 8 −0.80 0.42 1 6 6 . 2 ± 3 6 . 5 1 8 4 . 5 ± 3 6 . 0 −2.67 0.01
 Hb (g/dL) 1 1 . 4 ± 2 . 4 1 2 . 1 ± 2 . 3 −1.04 0.30 1 1 . 3 ± 2 . 7 1 2 . 1 ± 3 . 0 −0.94 0.35
 Preprandial blood glucose  level (mg/dL) 9 0 . 4 ± 1 7 . 1 8 6 . 1 ± 1 4 . 0 −0.73 0.46 7 9 . 0 ± 2 6 . 8 8 0 . 7 ± 7 . 1 −0.45 0.66
 BMI 2 1 . 8 ± 3 . 8 2 0 . 8 ± 3 . 6 −1.85 0.06 2 2 . 7 ± 6 . 0 2 1 . 9 ± 5 . 9 −1.10 0.27
CP: chlorpromazine, BP: biperiden, BPRS: brief psychiatric rating scale, TP: total protein, ALB: albumin, A/G ratio: albumin-globulin ratio, T-cho: total cholesterol, Hb: hemoglobin, and BMI: body mass index. *two-tailed asymptotic significance probability (Wilcoxon signed-rank test).